File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and Safety of Dabigatran, Rivaroxaban and Warfarin for Stroke Prevention in patients with Atrial Fibrillation: The Hong Kong Atrial Fibrillation Project.

TitleEfficacy and Safety of Dabigatran, Rivaroxaban and Warfarin for Stroke Prevention in patients with Atrial Fibrillation: The Hong Kong Atrial Fibrillation Project.
Authors
Li, WHuang, DChiang, CELau, CPTse, HFChan, EWWong, ICKLip, GChan, PHMSiu, DCW
KeywordsAtrial fibrillation
Intracranial hemorrhage
Ischemic stroke
Non-vitamin K antagonist oral anticoagulants
Issue Date2017
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/113412417/home
Citation
Clinical Cardiology (Hoboken), 2017, v. 40 n. 4, p. 222-229 How to Cite?
DOI: http://dx.doi.org/10.1002/clc.22649
Persistent Identifierhttp://hdl.handle.net/10722/241591
ISSN
0160-9289
2021 Impact Factor: 3.287
2020 SCImago Journal Rankings: 1.263
ISI Accession Number ID
WOS:000399666000006

 

DC FieldValueLanguage
dc.contributor.authorLi, W-
dc.contributor.authorHuang, D-
dc.contributor.authorChiang, CE-
dc.contributor.authorLau, CP-
dc.contributor.authorTse, HF-
dc.contributor.authorChan, EW-
dc.contributor.authorWong, ICK-
dc.contributor.authorLip, G-
dc.contributor.authorChan, PHM-
dc.contributor.authorSiu, DCW-
dc.date.accessioned2017-06-20T01:45:47Z-
dc.date.available2017-06-20T01:45:47Z-
dc.date.issued2017-
dc.identifier.citationClinical Cardiology (Hoboken), 2017, v. 40 n. 4, p. 222-229-
dc.identifier.issn0160-9289-
dc.identifier.urihttp://hdl.handle.net/10722/241591-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/113412417/home-
dc.relation.ispartofClinical Cardiology (Hoboken)-
dc.rightsClinical Cardiology (Hoboken). Copyright © John Wiley & Sons, Inc..-
dc.rightsPreprint: This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Postprint: This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Special Statement for Preprint only Before publication: 'This is a preprint of an article accepted for publication in [The Journal of Pathology] Copyright © ([year]) ([Pathological Society of Great Britain and Ireland])'. After publication: the preprint notice should be amended to follows: 'This is a preprint of an article published in [include the complete citation information for the final version of the Contribution as published in the print edition of the Journal]' For Cochrane Library/ Cochrane Database of Systematic Reviews, add statement & acknowledgement : ‘This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 20XX, Issue X. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.’ Please include reference to the Review and hyperlink to the original version using the following format e.g. Authors. Title of Review. Cochrane Database of Systematic Reviews 20XX, Issue #. Art. No.: CD00XXXX. DOI: 10.1002/14651858.CD00XXXX (insert persistent link to the article by using the URL: http://dx.doi.org/10.1002/14651858.CD00XXXX) (This statement should refer to the most recent issue of the Cochrane Database of Systematic Reviews in which the Review published.)-
dc.subjectAtrial fibrillation-
dc.subjectIntracranial hemorrhage-
dc.subjectIschemic stroke-
dc.subjectNon-vitamin K antagonist oral anticoagulants-
dc.titleEfficacy and Safety of Dabigatran, Rivaroxaban and Warfarin for Stroke Prevention in patients with Atrial Fibrillation: The Hong Kong Atrial Fibrillation Project.-
dc.typeArticle-
dc.identifier.emailLi, W: lazylwh@hku.hk-
dc.identifier.emailHuang, D: huangduo@hku.hk-
dc.identifier.emailLau, CP: cplau@hku.hk-
dc.identifier.emailTse, HF: hftse@hkucc.hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailChan, PHM: phmchan@hku.hk-
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hk-
dc.identifier.authorityTse, HF=rp00428-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityChan, PHM=rp01864-
dc.identifier.authoritySiu, DCW=rp00534-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/clc.22649-
dc.identifier.pmid27893153-
dc.identifier.scopuseid_2-s2.0-85006124430-
dc.identifier.hkuros272543-
dc.identifier.volume40-
dc.identifier.issue4-
dc.identifier.spage222-
dc.identifier.epage229-
dc.identifier.isiWOS:000399666000006-
dc.publisher.placeUnited States-
dc.identifier.issnl0160-9289-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats